Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2024-09-12 Regulatory Filings
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
HOLDING(S) IN COMPANY
Regulatory Filings
2024-09-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 8480D' by Indivior PLC on 12 September 2024. It details an acquisition or disposal of voting rights by BlackRock, Inc., crossing a threshold (from 5.03% down to below 5%). This type of mandatory disclosure regarding changes in significant share ownership is specifically covered by the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-09-12 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2024-09-10 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states it is a 'SHARE REPURCHASE PROGRAM WEEKLY REPORT' from Indivior PLC. It details the number of ordinary shares purchased for cancellation during a specific weekly period (September 2, 2024, up to and including September 6, 2024) as part of a Share Repurchase Program. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase reports. Although it is a weekly report, the content is the transaction detail itself, not an announcement of the report's publication (RPA) or a general regulatory filing (RNS).
2024-09-10 English
INDIVIOR PROVIDES UPDATE ON AEF0117
Regulatory Filings
2024-09-04 English
Indivior Provides Update on AEF0117
Legal Proceedings Report Classification · 99% confidence The document is identified by the RNS Number header and the explicit mention that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. The content announces clinical trial results (Phase 2B study results for AEF0117) and the company's resulting decision regarding an option exercise. This type of material, which is a formal, time-sensitive announcement to the market regarding material non-public information (inside information under MAR), fits best under the general 'Regulatory Filings' category (RNS) as it is a regulatory news service release, rather than a specific financial report (like 10-K or IR) or a management discussion (MDA). It is not a Call Transcript (CT), Earnings Release (ER), or a specific legal/director dealing report. Since RNS is the source and the format is a regulatory news announcement, RNS is the most appropriate code.
2024-09-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.